June 26, 2021
Video
The vice president of Medical Affairs in Migraine at Impel discussed the clinical takeaways from the STOP 301 trial of intranasal DHE and the advantages that the novel formulation might offer patients with migraine.
June 23, 2021
Video
The vice president of Medical Affairs in Migraine at Impel discussed the STOP 301 trial of intranasal DHE and how the safety profile offers a positive for patients who would use the agent on-demand.
June 22, 2021
Video
The vice president of Medical Affairs in Migraine at Impel discussed the gaps in care that novel dihydroergotamine formulations, such as INP104, might be able to fill for patients with migraine.
Serum Neurofilament Light Poses as Critical Biomarker During Ataxic, Preataxic Stages of Spinocerebellar Ataxias
Connecting ALS: How New Drug Coverage Decisions Are Made
NeuroVoices: Mark Lew, MD, on the Validation of Tears as a Biomarker for Parkinson Disease
AlzoSure Predict Test Shows Predictive Ability for Alzheimer Disease Years Prior to Diagnosis